p53 Oligomerization Domain Mutants: A New Class of Mutants That Retain "License to Kill"

Cancer Discov. 2023 May 4;13(5):1046-1048. doi: 10.1158/2159-8290.CD-23-0200.

Abstract

In this issue of Cancer Discovery, companion articles from the Prives and Lozano groups describe functional analyses of a common dimeric mutant of p53 found in Li-Fraumeni disease and sporadic cancer: A347D (AD). The authors show that the AD mutant is completely defective for canonical p53 transcriptional function, but interestingly retains some tumor suppressor function, which they show is manifested as "neomorphic" activities in transcription and the control of mitochondrial metabolism. See related article by Gencel-Augusto et al., p. 1230 (7). See related article by Choe et al., p. 1250 (6).

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cell Death
  • Humans
  • Li-Fraumeni Syndrome* / metabolism
  • Transcriptional Activation
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Tumor Suppressor Protein p53